Showing the latest 10 filings. Sign in to filter or browse the full history. View full history
Showing 10 of 47 filings.
13 Aug 2026 1 filing
Financial Performance
Consolidated revenue: INR 925 crores, up 16% YoY.
EBITDA: INR 94 crores; YoY -7%; QoQ +25%.
PAT: INR 22 crores; YoY >2x.
Order intake: INR 1,007 crores in Q1; flat YoY.
Backlog: INR 2,289 crores; +20% YoY; +4% QoQ.
Division Highlights
CRT revenue: INR 466 crores, +10% YoY; CRT orders: INR 502 crores, +23%.
PPT revenue: INR 255 crores, +23%; PPT orders: INR 367 crores, +64%.
HET revenue: INR 74 crores, flat; HET orders: INR 58 crores, >700% YoY.
PST revenue: INR 131 crores, +46%; PST orders: INR 80 crores.
Execution and Backlog Timing
Order backlog executable profile: majority of Q1 intake executable in FY27.
Division-wise orders indicate 10–12 month execution cycles.
Balance Sheet and Cash Flow
Debt plan: repay ~EUR 7 million by end of Q2 FY27; refinance to optimize debt maturity.
Focus on strengthening balance sheet; cash generation and working-capital discipline.
Guidance and Outlook
Target EBITDA margin: minimum 15%; path to improve across divisions.
Tax rate around 30% long term; stabilization expected in 18–24 months.
Q&A Highlights
Q: Recovery in traditional markets? A: Pharma improving in India; international pharma improving; chemicals flat.
Q: Indian margin pressure due to transformation costs; expected recovery? A: margins should improve with utilization and pricing.
Q: Bottlenecks before reorganization? A: regional structure hindered cross-division work; now KPIs aligned.
Q: Backlog execution risk; 10–12 month horizon? A: majority executable in 10–12 months.
Q: Debt targets and timelines? A: EUR 7m repayment planned; 12–18 months to deleverage; debt target not disclosed.
Q: Tax rate trajectory? A: around 30%; stabilization in 18–24 months.
6 Aug 2026 2 filings
Meeting Details
Date/time: August 6, 2026, 12:00 IST.
Type/mode: group earnings conference call, virtual.
Event: Q1 FY27 Earnings Conference Call – Audio Recording (GMM Pfaudler).
Purpose
Purpose: earnings results discussion for Q1 FY27.
Additional Notes
Audio recording of the call is available on the company website.
28 Jul 2026 1 filing
Meeting Details
Results announced on August 5, 2026; earnings call on August 6, 2026 at 12:00 IST.
Type: earnings call; mode: virtual.
Participants: company management to host the call.
Event/organiser: GMM Pfaudler.
15 Jul 2026 1 filing
Dematerialisation status
Dematerialisation requests for quarter ended 30 June 2026 were processed and confirmed to the depositories.
Securities dematerialised have been listed on the stock exchanges where the existing securities are listed.
Physical demat certificates were mutilated and cancelled; depository name updated as registered owner within timelines.
Rematerialisation requests received: none.
10 Jul 2026 2 filings
Overview
Global provider of process technologies, systems, and services for chemical, pharma, energy, and industrial sectors.
Reporting scope: standalone BRSR for FY26 (year ended March 31, 2026).
Key ESG Risks & Opportunities
Climate change risk with physical impacts; mitigated by energy efficiency, renewables, water and waste circularity.
Energy & emissions opportunity: renewable share 14.16% and 1,695.6 tCO2e avoided; ongoing efficiency programs.
Water management: wastewater treatment and recycling; Karamsad plant implements Zero Liquid Discharge.
Waste management: waste minimization; TSDF disposal; limited end-of-life reclamation for products.
Governance & supply chain: ESG Strategy 2.0; MD-chaired Steering Committee; 49.11% inputs from suppliers assessed for sustainability.
R&D & innovation: emphasis on sustainable design and energy-efficient process improvements.
Governance & Policy Highlights
Board approved ESG Strategy 2.0; ESG Steering Committee oversees implementation.
Key policies: Anti-Bribery & Anti-Corruption, Whistle Blower, Human Rights, Code of Conduct, Supplier Code of Conduct.
Certifications: ISO 9001, ISO 14001, ISO 45001; NVG alignment; policies approved by Board.
Compliance: no material fines or penalties in FY26; no anti-competitive orders reported.
Assurance: internal audits; external assessments conducted as needed; governance reinforced by continuous monitoring.
Social Responsibility & Workforce
Workforce: 633 total; 626 permanent; 2,141 workers; women 5.69% of permanent staff.
Diversity: board female representation 25%; key management female 33%.
Health & safety: ISO 45001 certified; 17 total worker injuries; no fatalities; emergency readiness ongoing.
Well-being & training: health benefits, wellness programs, DE&I, leadership development; regular training.
CSR focus: healthcare (55,000+ beneficiaries), education (1,400+), environment initiatives.
Environmental Performance
Energy: total 227,476.95 GJ; renewables 8,601.60 GJ; renewables share 14.16%.
GHG emissions: Scope 1 10,048.73 tCO2e; Scope 2 10,282.69 tCO2e; Scope 1+2 intensity 19.66 tCO2e/Cr turnover.
Water: total withdrawal 56,102.66 kilolitres; groundwater 16,722; third-party water 39,380.66; ZLD at Karamsad plant.
Waste: total 2,651.58 MT; recycled 1.87 MT; reused 79.83 MT; landfill 21.73 MT.
Certifications and initiatives: ISO 9001/14001/45001; wind-solar hybrid and captive solar projects.
Stakeholder Engagement & Complaints
Stakeholders include investors, employees, customers, suppliers, communities; engagement via emails, meetings, website.
ESG Strategy 2.0 approved; quarterly Board reviews; ESG Steering Committee coordinates stakeholder engagement.
Grievance mechanisms exist across groups; community and value-chain feedback integrated into policy and actions.
Vulnerable groups addressed through CSR programs; ongoing collaboration with communities and local partners.
Other Notable Metrics
Sustainable inputs: 49.11% of inputs from sustainability-assessed suppliers; 24.19% MSMEs; 78.78% Indian sourcing.
Data privacy: cyber security policy; no data breaches reported to CERT-In in FY26.
Affiliations: member of 12 trade/industry chambers; top bodies include FICCI, CII, ICC, PPMAI, IACC, and others.
Product recalls: none; customer information on products/services provided via manuals and training.
AGM details
63rd AGM on Aug 4, 2026 at 12:00 IST; Mode: VC/OAVM.
Record date: 28 July 2026; books closed 29 July–4 Aug 2026; e-voting 31 July–Aug 3.
Resolutions to be put to vote
Receive and adopt Audited Standalone and Consolidated Financial Statements.
Confirm interim dividend; declare final dividend for FY2026.
Re-appoint Ramdev as Director (retiring by rotation).
Ratify remuneration to Cost Auditors for FY2026-27.
Special: Appoint Gregory Gelhaus as Group CEO (related party).
Director & KMP changes
Aseem Joshi resigned as CEO; Tarak Patel remains MD.
Ankit Nayyar appointed Deputy CFO; effective 21 May 2026.
Auditors
Statutory auditors: S R B C & Co LLP; five-year term 2025–2030.
29 Jun 2026 1 filing
Trading window closes for designated persons from June 30, 2026 until 48 hours after Q1 FY27 results declaration.